Subscribe To
Isoray inc. and viewpoint molecular targeting inc. announce name change to perspective therapeutics inc.
Company’s focus is on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies New corporate tagline and...
February 7, 2023, 10:48 pm
Essa pharma: one asset, one program company with little data
EPIX is targeting prostate cancer with its lead and only asset EPI-7386. While there's some rationale to the m...
February 6, 2023, 8:28 am
Why is genetic technologies (gene) stock up 173% today?
Genetic Technologies (NASDAQ: GENE ) stock is taking off on Friday as the company prepares for new cancer tests areas. The big news here is Genetic Te...
February 3, 2023, 8:35 am
Kalvista pharmaceuticals to present at svb securities global biopharma conference
CAMBRIDGE, Mass. & SALISBURY, England--( BUSINESS WIRE )--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focus...
February 3, 2023, 6:30 am
Structure therapeutics announces pricing of upsized initial public offering
SAN FRANCISCO and SHANGHAI, China, Feb. 02, 2023 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceu...
February 3, 2023, 12:41 am
Onl therapeutics receives u.s. fda clearance of investigational new drug application for onl1204 ophthalmic solution
First-in-class small molecule Fas inhibitor with unique mechanism of action is designed to provide neur...
February 1, 2023, 12:00 pm
Enveric biosciences to present at the bio ceo & investor conference
CAMBRIDGE, Mass.--( BUSINESS WIRE )--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the...
February 1, 2023, 7:33 am
Zentalis pharmaceuticals to participate in two upcoming investor conferences
NEW YORK and SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company fo...
February 1, 2023, 7:01 am
Biomarin: priced for perfection
BioMarin has a core cadre of molecules with modestly growing revenues. Its VOXZOGO has clear blockbuste...
January 31, 2023, 7:28 pm
C4 therapeutics announces first patient dosed in phase 1/2 clinical trial evaluating cft1946, an orally bioavailable bidac™ degrader, in braf v600 mutant solid tumors
WATERTOWN, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated ...
January 30, 2023, 12:00 pm
Purple city labs introduces onsight, a molecular assay for in-house testing of hop latent viroid
OAKLAND, Calif., Jan. 27, 2023 (GLOBE NEWSWIRE) — Purple City Labs, a plant molecular biology company...
January 28, 2023, 1:12 am
Schrodinger: unlocking the potential of computer-assisted drug discovery during tough times
Schrodinger has developed a software platform that uses advanced physics and machine learning methods to predict important aspects of ...
January 24, 2023, 8:28 am
Regen biopharma, inc. to present at the emerging growth conference on january 25, 2023
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentatio...
January 23, 2023, 2:46 pm
Matinas biopharma to provide corporate update and 2023 business outlook on january 30, 2023
Conference call and live audio webcast scheduled for Monday, January 30th at 4:30 p.m. ET BEDMINSTER, N.J., Jan. 23, 2023 (GLOBE NEWSWIRE) — Matinas...
January 23, 2023, 12:00 pm
Salarius pharmaceuticals to present sp-3164 targeted protein degrader preclinical data at the inaugural molecular glue drug development summit
Dr. Aundrietta Duncan to discuss mechanism of action and SP-3164 activity in cancer models Company planning to submit an Investigational New Drug appl...
January 19, 2023, 1:30 pm
Salarius pharmaceuticals to present sp-3164 targeted protein degrader preclinical data at the inaugural molecular glue drug development summit
Dr. Aundrietta Duncan to discuss mechanism of action and SP-3164 activity in cancer models...
January 19, 2023, 8:30 am
Opgen subsidiary curetis meets several key milestones in find collaboration project
Successful delivery of milestones triggers milestone payment ROCKVILLE, Md., Jan. 17, 2023 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen”...
January 17, 2023, 12:30 pm
Avalon globocare says it has been issued with a us patent for multiple novel qty-code modified cytokine and chemokine protein receptor molecules
Avalon GloboCare Corp (NASDAQ:ALBT) has announced that the US Patent and Trademark Office (USPTO) has issued it with US Patent No. 11,555,060, titled ...
January 17, 2023, 9:13 am
molecular partners initiates clinical study of trispecific candidate mp0533 for the treatment of acute myeloid leukemia
Unique avidity driven mechanism engages CD3 on T cells when binding either two or three tumor-associated antigens to enhance selectivity for AML cells...
January 16, 2023, 6:00 am
Ventyx: focusing on competitive differences will help
Ventyx Biosciences, Inc. has three interesting molecules in inflammatory diseases. Each is in a differe...
January 13, 2023, 3:52 pm